Melanotan I — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Melanotan I

Also known as: MT-I, MTI, NDP-MSH, NDP-α-MSH, [Nle4,D-Phe7]-α-MSH, [Nle4-D-Phe7]-alpha-MSH, afamelanotide (approved form), MELANOTAN

Synthetic melanocortin peptide; MC1R agonist; alpha-MSH analogue (linear)

Research chemicalLast updated: October 19, 2026Based on 29 peer-reviewed studies

What it is

Melanotan I is a peptide people use to stimulate skin tanning without sun exposure. Research has also explored it for photoprotection and sexual dysfunction. Not FDA-approved; a related compound (afamelanotide) is approved in Europe for a rare sun-sensitivity disorder; regulatory status of Melanotan I itself is unverified.

The scientific side

Melanotan I ([Nle4,D-Phe7]-α-MSH; NDP-MSH) is a superpotent, enzymatically resistant synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH) that binds to and activates the melanocortin 1 receptor (MC1R) with high affinity (binding IC50 ~1.2 nM; cAMP EC50 ~0.5 nM at hMC1R). Binding to MC1R stimulates adenylate cyclase, elevating intracellular cAMP, which drives melanogenesis and increases eumelanin content in skin (PMID 41489668, PMID 26293341). Unlike the endogenous α-MSH, Melanotan I incorporates norleucine at position 4 and D-phenylalanine at position 7, conferring superpotency and enzymatic stability (PMID 9760697, PMID 16412534). It also activates other melanocortin receptor subtypes (MC3R, MC4R, MC5R) to varying degrees (PMID 7980588, PMID 39296259). Additional reported biological activities include anti-inflammatory effects via modulation of cytokine and matrix metalloproteinase expression in human chondrocytes, modulation of feed intake and insulin action via central melanocortin pathways in animal models, and neuroprotective effects reported in preclinical models (PMID 36703981, PMID 38688422).

Class: Synthetic melanocortin peptide; MC1R agonist; alpha-MSH analogue (linear)

Administration & storage

Administration
Subcutaneous injection (PMID: 9113347PMID: 1658407PMID: 11045725PMID: 30142729PMID: 19224885PMID: 20545686)Intravenous injection (PMID: 9113347)Oral administration — no detectable plasma levels observed (PMID: 9113347)Intracerebroventricular infusion in animal studies (PMID: 38035762)Intraperitoneal injection in animal studies (PMID: 36703981PMID: 38688422)Transdermal — in vitro permeation through human skin demonstratednot validated clinically (PMID: 2155969)
Storage
No storage conditions for Melanotan I are specified in the reviewed abstracts. The HPLC analytical study assessed drug stability in biological matrices (cell culture media and human plasma) and the assay was described as 'stability-indicating,' but specific storage temperature or shelf-life data are not reported in the abstract.
Cautions
Unregulated Melanotan I sold online has unknown purity, preparation quality, and actual dose content — multiple national health organizations have issued safety warnings.,Case reports describe activation/changes in dysplastic nevi and newly emerging (dysplastic) nevi during or shortly after use; four cases of melanoma emerging from existing moles reported in association with melanotan use, though conclusive causal evidence is lacking (PMID: 28266027, PMID: 26315100).,Melanotan-associated transverse melanonychia (nail pigmentation change) has been reported as a case finding.,No detectable drug levels were observed following oral dosing, indicating this route is not effective for absorption; IV and SC routes were the only routes showing systemic absorption in pharmacokinetic studies.,The MHRA has raised awareness of the public health risk of blood-borne virus transmission from needle sharing among illicit users, and of potential product impurity.,Sterile technique is essential for any injected preparation; unverified internet-sourced peptides carry unknown contamination risks.

Legal & regulatory status

US FDA

Not stated in reviewed literature as currently FDA-approved under the name Melanotan I. Abstract 59 notes NDP-α-MSH as a peptide agonist, and Abstract 55 refers to NDP-MSH as a tool compound. Abstract 1 states…

WADA

Not stated in reviewed literature — requires manual verification.

Health Canada

Not stated in reviewed literature — requires manual verification.